Introduction
============

Degenerative scoliosis develops after skeletal maturity without a previous history of scoliosis and typically presents in the lumbar or thoracolumbar spine ([@b1-etm-05-03-0977],[@b2-etm-05-03-0977]). The etiology of degenerative lumbar scoliosis (DLS) remains unclear, although several factors, including hormones, genetics and degenerative diseases of the spine, may be involved ([@b3-etm-05-03-0977]). It has been suggested that the cause of DLS is associated with disc degeneration and osteoporosis ([@b4-etm-05-03-0977]).

During an individual's lifetime, modeling, remodeling and repair of the bone occur as a result of the activity of osteoclasts and osteoblasts ([@b5-etm-05-03-0977]). The control of bone remodeling is performed by a few neurotransmitters, such as glutamate, via corresponding receptors in the bone cells ([@b6-etm-05-03-0977]). Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS) ([@b7-etm-05-03-0977]) and acts through a variety of receptors including N-methyl-D-aspartate (NMDA) receptors. The NMDA receptors (NMDARs) are composed of NMDAR1, NMDAR2 and NMDAR3 and are expressed in the bone cells ([@b8-etm-05-03-0977],[@b9-etm-05-03-0977]). In addition, glutamate is a known regulator of the maturation and differentiation of osteoclasts and osteoblasts ([@b10-etm-05-03-0977],[@b11-etm-05-03-0977]).

We hypothesized that genetic polymorphisms in the *NMDAR* genes may be associated with DLS. However, there have been no published studies concerning the association between DLS and single nucleotide polymorphisms (SNPs) of *NMDAR* genes. Therefore, the 9 coding SNPs (cSNPs) of *NMDAR2A* (*GRIN2A*), *NMDAR2B* (*GRIN2B*) and *NMDAR2C* (*GRIN2C*) were analyzed in 70 patients with DLS and 141 control subjects.

Materials and methods
=====================

Subjects
--------

The DLS group comprised 70 unrelated individuals (10 males and 60 females), aged 52--82 years (mean ± SD, 67.63±7.05 years). The DLS patients were selected from the Spine Center of Kyung Hee University East-West Neo Medical Center (Seoul, Korea) and the National Medical Center (Seoul, Korea), out of ∼9,000 patients per year over three years. Each patient was diagnosed by two specialized spine surgeons and all patients fulfilled the physical examination and radiographic criteria (Cobb's angle, \>10°). Informed consent was obtained from all individuals according to the Declaration of Helsinki guidelines. The study was approved by the Ethics Review Committee of the Medical Research Institute, Kyung Hee University Medical Center (Seoul, Korea). The control group comprised 141 individuals (25 males and 116 females), aged 53--85 years (mean ± SD, 66.74±8.23 years). Control group individuals were recruited following a general health check-up program to confirm that they had no clinical evidence of DLS according to radiographic criteria. The ages and genders of the control group individuals were matched to those of the DLS group ([Table I](#t1-etm-05-03-0977){ref-type="table"}).

SNP genotyping
--------------

The cSNPs of *GRIN2A*, *GRIN2B* and *GRIN2C* were searched. Information relating to the cSNPs was obtained from the SNP database ([www.ncbi.nlm.nih.gov/SNP](www.ncbi.nlm.nih.gov/SNP); dbSNP Build 130) of the National Center for Biotechnology Information (NCBI). cSNPs with unknown heterozygosity and minor allele frequencies (\<5%) were excluded. Finally, 9 cSNPs were selected \[*GRIN2A* (rs8049651, Leu425Leu; rs9806806, Tyr730Tyr); *GRIN2B* (rs7301328, Pro122Pro; rs35025065, Asp447Asp; rs1805522, Ile602Ile; rs1806201, Thr888Thr; rs1805247, His1399His); and *GRIN2C* (rs689730, Ala33Ala; rs3744215, Arg1209Ser)\] for analysis. Genomic DNA was extracted from blood samples collected in EDTA using a commercially available Qiagen DNA extraction kit (Qiagen, Tokyo, Japan). Genomic DNA was amplified using primers for each cSNP ([Table II](#t2-etm-05-03-0977){ref-type="table"}). The PCR products were sequenced using an ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster City, CA, USA). Sequence data were analyzed using SeqManII software (DNASTAR Inc., Madison, WI, USA).

Statistical analysis
--------------------

The Hardy-Weinberg equilibrium (HWE) was assessed using SNPStats (<http://bioinfo.iconcologia.net/snpstats>) ([@b12-etm-05-03-0977]). Multiple logistic regression models (codominant, dominant and recessive) were used to calculate the odds ratio (OR), 95% confidence interval (CI) and corresponding P-values, with age and gender as covariables. To analyze the associations of cSNPs and haplotypes, SNPStats, HapAnalyzer and HelixTree (Golden Helix, Inc., Bozeman, MT, USA) were used.

Results
=======

Of the nine cSNPs of *GRIN2A*, *GRIN2B* and *GRIN2C* genes examined, eight were polymorphic and one (rs35025065) was monomorphic ([Table III](#t3-etm-05-03-0977){ref-type="table"}). The genotype distributions of the eight cSNPs were in HWE (P\>0.05, data not shown).

As shown in [Table III](#t3-etm-05-03-0977){ref-type="table"}, there was no significant difference in the genotypic frequency of polymorphism rs8049651 between the DLS (CC 87%, CG 13% and GG 0%) and control groups (CC 87%, CG 11% and GG 1%; P=0.76). Additionally, the other seven cSNPs were not associated with DLS. Via the Gabriel method ([@b13-etm-05-03-0977]), two cSNPs (rs1805247 and 1806201 of GRIN2B) were used to construct a one linkage disequilibrium (LD) block (data not shown). Three haplotypes in the block had frequencies \>0.1. However, there was no significant difference in haplotype frequencies between the DLS and control groups (data not shown).

However, when DLS patients were divided into two groups according to clinical characters based on Cobb's angle (\<20° or ≥20°) and lateral listhesis (\<6 mm or ≥6 mm), associations were observed between the *GRIN2B* and *GRIN2C* polymorphisms and clinical characteristics. As shown in [Table IV](#t4-etm-05-03-0977){ref-type="table"}, rs689730 of *GRIN2C* was associated with Cobb's angle in the codominant (P=0.038; OR, 2.72; 95% CI, 0.98--7.55) and dominant models (P=0.022; OR, 3.79; 95% CI, 1.15--12.54). The present study showed that the CT or TT genotype frequency with Cobb's angle ≥20° was ∼2-fold higher than with Cobb's angle \<20°. In the analysis of lateral listhesis, rs7301328 of *GRIN2B* showed significant differences in the codominant (P=0.0027; OR, 3.21; 95% CI, 1.41--7.29), dominant (P=0.015; OR, 3.91; 95% CI, 1.22--12.51) and recessive models (P=0.015; OR, 5.39; 95%CI, 1.26--23.08). The results indicated that the CC genotype frequency with lateral listhesis ≥6 mm was ∼4-fold higher than with lateral listhesis \<6 mm ([Table IV](#t4-etm-05-03-0977){ref-type="table"}).

Discussion
==========

A number of individuals present degenerative diseases of the spine, such as spondylolisthesis, lateral listhesis, spinal stenosis and degenerative scoliosis with increasing age ([@b3-etm-05-03-0977],[@b14-etm-05-03-0977]). Scoliosis is a spinal deformity with lateral curvature or angulation and may be accompanied by rotation of the affected vertebrae in the vertical axis ([@b15-etm-05-03-0977]).

Complicated DLS induces severe back or leg pain with neurological deficits by compressing neural elements and causing nerve root ischemia ([@b16-etm-05-03-0977]). Despite uncertainty with regard to the etiology of DLS, degeneration of the spinal column occurs in the development of the disease ([@b3-etm-05-03-0977]). Considering that the etiology of DLS is unclear, the identification of candidate genes associated with the development of DLS may potentially be used to identify at-risk individuals. Therefore, the potential of *NMDAR2* genes as candidate genes in the development of DLS was investigated through a case-control analysis in the current study.

Glutamate is the most prominent excitatory neurotransmitter in the CNS. It has been studied intensively in a number of neuropathological conditions, including stroke, epilepsy and neurodegenerative diseases ([@b17-etm-05-03-0977],[@b18-etm-05-03-0977]). Glutamate exerts its effects through ionotropic ligand-gated ion channels and metabotropic G-protein-coupled glutamate receptors. The ionotropic receptors are further divided into NMDA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainate receptors ([@b19-etm-05-03-0977]--[@b21-etm-05-03-0977]). Spencer *et al*([@b6-etm-05-03-0977]) conducted a review of NMDA-type glutamate signalling.

In the current study, 9 cSNPs in the genes *GRIN2A*, *GRIN2B* and *GRIN2C* were analyzed to assess the association between these polymorphisms and DLS. The *GRIN2A*, *GRIN2B* and *GRIN2C* genes are located on chromosomes 16p13.2, 12p12 and 17q25, respectively. In the coding regions of each gene, 15, 22 and 14 cSNPs have been discovered, respectively. Of these 51 cSNPs, 9 exhibited heterozygosity \>0.1 ([www.ncbi.nlm.nih.gov/SNP](www.ncbi.nlm.nih.gov/SNP), dbSNP Build 130) and were selected for analysis in thist study. Overall, none of the genotype frequencies or haplotype distributions of the NMDRs (*GRIN2A*, *GRIN2B* and *GRIN2C*) were observed to be associated with DLS.

Several studies have shown associations between SNPs of *GRIN2A* and/or *GRIN2B* and neurological or psychiatric diseases, such as Huntington's disease ([@b22-etm-05-03-0977]), schizophrenia ([@b23-etm-05-03-0977]), bipolar disorder ([@b24-etm-05-03-0977]) and Alzheimer's disease ([@b25-etm-05-03-0977]). In addition, Kim *et al*([@b26-etm-05-03-0977]) reported that rs1806201 of *GRIN2B* was associated with alcoholism in a Korean population, but rs18054247 was not. However, Tadic *et al*([@b27-etm-05-03-0977]) reported that rs1806201 was not associated with alcohol dependence, alcohol withdrawal-induced seizures and delirium tremens in a Caucasian population.

The possible associations between nine cSNPs of *GRIN2A*, *GRIN2B* and *GRIN2C* genes and DLS were investigated, but the results were negative. To compare each genotype frequency in various ethnic populations, the human SNP database ([www.ncbi.nlm.nih.gov-SNP](www.ncbi.nlm.nih.gov-SNP), dbSNP Build 130) was searched. The genotype distributions of all cSNPs in the control group were similar to those of the Asian populations, particularly the Japanese population (data not shown).

When the patients were divided into two groups according to clinical characteristics (Cobb's angle and lateral listhesis), *GRIN2B* and *GRIN2C* were associated with the severity of DLS. As shown in [Table IV](#t4-etm-05-03-0977){ref-type="table"}, rs689730 of GRIN2C was associated with Cobb's angle in the codominant (P=0.038) and dominant models (P=0.022). Furthermore, rs7301328 of *GRIN2B* was associated with lateral listhesis in the codominant (P=0.003), dominant (P=0.015) and recessive models (P=0.015).

The present results indicate that *GRIN2A*, *GRIN2B* and *GRIN2C* do not affect the development of DLS in the Korean population. However, significant associations were observed between *GRIN2C* and Cobb's angle and between *GRIN2B* and lateral listhesis in DLS.
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###### 

Characteristics of DLS and control subjects.

  Factor                              DLS (n=70)   Controls (n=141)
  ----------------------------------- ------------ ------------------
  Age (years, mean ± SD)              67.63±7.05   66.4±8.23
  Gender (male/female)                10/60        25/116
  Cobb's angle (°, mean ± SD)         17.07±2.95   NA
  Lateral listhesis (mm, mean ± SD)   4.78±2.30    NA

DLS, degenerative lumbar scoliosis; NA, not applicable.

###### 

Sequences of primers for cSNPs of *GRIN2A*, *GRIN2B* and *GRIN2C* genes.

  Gene                    SNP                      Direction                Sequence (5′→3′)         Size (bp)
  ----------------------- ------------------------ ------------------------ ------------------------ -----------
  *GRIN2A*                rs8049651, Leu425Leu     Forward                  GATTTGCCTCTCCAGAAATCAG   321
  Reverse                 CTATTTCAAAGGGTTGGGCACG                                                     
  rs9806806               Forward                  TGCATGCATTTACCTCCTAACA   380                      
  Tyr730Tyr               Reverse                  AATGGGAGCAGATAGGAACTGA                            
  *GRIN2B*                rs7301328, Pro122Pro     Forward                  CGAGAAAGATGATTTCCACCAT   391
  Reverse                 GATTAATTGCTGGCCTATCCAC                                                     
  rs35025065, Asp447Asp   Forward                  GGTCTGTTGCCTGCTTTATTTC   322                      
  Reverse                 CAGGTTCCATTGATTTTCTTCC                                                     
  rs1805522, Ile602Ile    Forward                  TGAGAGTCCCTGGAAAAGAGAG   392                      
  Reverse                 CCAGAAACCTGGTCCACATATT                                                     
  rs1806201, Thr888Thr    Forward                  TTGTGGTCATTTCTAGCCTCTC   371                      
  Reverse                 CCGAACGTTCTCTCTACCTCAC                                                     
  rs1805247, His1399His   Forward                  CCTACGCCCACATGTTTGAGAT   381                      
  Reverse                 GGTTTTTGTTGTTAGGCACACA                                                     
  *GRIN2C*                rs689730, Ala33Ala       Forward                  AACCTCTGTCTCTCTCCCTGTG   394
  Reverse                 GGAGATGAAGTCAAGGATCTGG                                                     
  rs3744215, Arg1209Ser   Forward                  CTGTCTGTCCTCACCTTCCACC   392                      
  Reverse                 CACCATGATTTGAGGCTACTGA                                                     

SNP, single nucleotide polymorphisms.

###### 

Genotype frequencies of cSNPs in *GRIN2A*, *GRIN2B* and *GRIN2C* genes.

                                                        DLS    Control                                                                            
  ----------------------- ---------------------- ------ ------ --------- ----------- -------------------- ------------------- ------------------- ------
  *GRIN2A*                rs8049651, Leu425Leu   C/C    61     0.87      123         0.87                 Codominant          0.88 (0.40--1.94)   0.76
  C/T                     9                      0.13   16     0.11      Dominant    0.99 (0.42--2.35)    0.99                                    
  T/T                     0                      0.00   2      0.01      Recessive   0.00 (0.00--NA)      0.17                                    
  rs9806806, Tyr730Tyr    C/C                    63     0.90   120       0.85        Codominant           0.60 (0.26--1.37)   0.20                
  C/G                     7                      0.10   18     0.13      Dominant    0.64 (0.25--1.59)    0.32                                    
  G/G                     0                      0.00   3      0.02      Recessive   0.00 (0.00--NA)      0.11                                    
  *GRIN2B*                rs7301328, Pro122Pro   C/C    12     0.18      31          0.22                 Codominant          0.86 (0.57--1.29)   0.46
  G/C                     32                     0.47   61     0.43      Dominant    0.91 (0.49--1.69)    0.77                                    
  G/G                     24                     0.35   49     0.35      Recessive   0.69 (0.32--1.46)    0.32                                    
  rs1805522, Ile602Ile    A/A                    5      0.07   7         0.05        Codominant           0.93 (0.57--1.51)   0.76                
  G/A                     16                     0.23   41     0.29      Dominant    0.84 (0.45--1.56)    0.58                                    
  G/G                     49                     0.70   93     0.66      Recessive   1.22 (0.36--4.16)    0.75                                    
  rs1806201, Thr888Thr    A/A                    14     0.21   34        0.24        Codominant           0.89 (0.58--1.36)   0.60                
  G/A                     37                     0.54   72     0.51      Dominant    0.95 (0.48--1.87)    0.88                                    
  G/G                     17                     0.25   34     0.24      Recessive   0.77 (0.38--1.57)    0.47                                    
  rs1805247, His1399His   A/A                    46     0.66   91        0.65        Codominant           0.84 (0.50--1.40)   0.50                
  A/G                     23                     0.33   42     0.30      Dominant    0.96 (0.53--1.77)    0.91                                    
  G/G                     1                      0.01   8      0.06      Recessive   0.20 (0.02--1.68)    0.08                                    
  *GRIN2C*                rs689730, Ala33Ala     C/C    36     0.54      81          0.58                 Codominant          1.28 (0.77--2.13)   0.34
  C/T                     26                     0.39   56     0.40      Dominant    1.14 (0.63--2.06)    0.66                                    
  T/T                     5                      0.07   3      0.02      Recessive   3.31 (0.76--14.48)   0.10                                    
  rs3744215, Arg1209Ser   G/G                    26     0.39   44        0.31        Codominant           0.97 (0.64--1.47)   0.88                
  G/T                     27                     0.40   74     0.52      Dominant    0.75 (0.41--1.39)    0.36                                    
  T/T                     14                     0.21   23     0.16      Recessive   1.38 (0.66--2.91)    0.40                                    

SNP, single nucleotide polymorphism; cSNPs, coding SNPs; DLS, degenerative lumbar scoliosis; freq, frequency; OR, odds ratio; 95% CI, 95% confidence interval; NA, not applicable.

###### 

Genotype frequencies of rs689730 and rs7301328 in DLS patients with Cobb's angle or lateral listhesis.

  A, Cobb's angle                                                                   
  ----------------- ----- ---- ------ ---- ------ ------------ -------------------- -------
  GRIN2C,           C/C   15   0.75   21   0.45   Codominant   2.72 (0.98--7.55)    0.038
  rs689730,         C/T   4    0.20   22   0.47   Dominant     3.79 (1.15--12.54)   0.022
  Ala33Ala          T/T   1    0.05   4    0.09   Recessive    1.82 (0.18--17.97)   0.590

  B, Lateral listhesis                                                                   
  ---------------------- ----- ---- ------ ---- ------ ------------ -------------------- -------
  GRIN2B,                C/C   3    0.08   9    0.32   Codominant   3.21 (1.41--7.29)    0.003
  rs7301328,             G/C   18   0.45   14   0.50   Dominant     3.91 (1.22--12.51)   0.015
  Pro122Pro              G/G   19   0.48   5    0.18   Recessive    5.39 (1.26--23.08)   0.015

DLS, degenerative lumbar scoliosis; SNP, single nucleotide polymorphism; freq, frequency. OR, odds ratio; 95% CI, 95% confidence interval.
